Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 529-538

  Fountzilas, George ^a   Bamias, Aristotelis ^b   Kalogera Fountzila, Anna ^a   Karayannopoulou, Georgia ^a   Bobos, Mattheos ^a   Athanassiou, Eleni ^c   Kalogeras, Konstantine T ^a,d   Tolis, Christos ^e   Tsekeris, Periklis ^e   Papakostas, Pavlos ^f   Vamvouka, Chrysanthi ^g   Zaramboukas, Thomas ^a   Kosmidis, Paris ^h   Zamboglou, Nikolaos ⁱ   Misailidou, Despina ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Agios Savvas Cancer Hospital   (Greece)

^d Hellenic Cooperative Oncology Group   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f HIPPOKRATION HOSPITAL   (Greece)

^g EVANGELISMOS HOSPITAL   (Greece)

^h HYGEIA HOSPITAL   (Greece)

ⁱ Klinikum Offenbach   (Germany)

Author keywords

Chemotherapy; Docetaxel; ERCC1; Head and neck cancer; Radiation therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; IFOSFAMIDE; ONDANSETRON;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HEART ARRHYTHMIA; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STOMATITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HEAD AND NECK NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; REMISSION INDUCTION; TAXOIDS;

EID: 61449249336     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
2. Monnerat C, Faivre S, Temam S, Bourhis Jand Raymond E: Endpoints for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 13: 995-1006, 2002.
3. Kim ES, Kies M and Herbst RS: Novel therapeutics for head and neck cancer. Curr Opin Oncol 14: 334-342, 2002.
4. Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
5. Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B and Nikolic N: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 43: 29-37, 1997.
6. Argiris A: Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol 14: 323-329, 2002.
7. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955, 2000.
8. Seiwert TY, Salama JK and Yokes EE: The concurrent chemoradiation paradigm - general principles. Nat Clin Pract Oncol 4: 86-100, 2007.
9. Seiwert TY, Salama JK and Yokes EE: The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 4: 156-171, 2007.
10. Fountzilas G, Tolis C, Kalogera-Fountzila A, Karanikiotis C, Bai M, Misailidou D, Samantas E, Athanassiou E, Papamichael D, Tsekeris P, Catodritis N, Nicolaou A, Plataniotis G, Makatsoris T, Papakostas P, Zamboglou N and Daniilidis J: Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group Phase II study. Strahlenther Onkol 181: 223-230, 2005.
11. Posner M: Evolving strategies for combined-modality therapy for locally advanced head and neck cancer. Oncologist 12: 967-974, 2007.
12. Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, Groult V, Bordessoule S, Janot F, De Forni M and Armand JP: A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 81: 457-462, 1999.
13. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R and Posner MR: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14: 1672-1678, 1996.
14. Fountzilas G, Tolis C, Kalogera-Fountzila A, Misailidou D, Tsekeris P, Karina M, Nikolaou A, Samantas E, Makatsoris T, Athanassiou E, Skarlos D, Bamias A, Zamboglou N, Economopoulos T, Karanastassi S, Pavlidis N and Daniilidis J: Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study. Med Oncol 22: 269-279, 2005.
15. Dabbs DJ (ed.): Diagnostic Immunohistochemistry, 1st edition. Churchill Livingstone: Philadelphia, PA. p39, 2002.
16. Skacel M, Skilton B, Pettay JD and Tubbs RR: Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol 10: 1-6, 2002.
17. Camp RL, Charette LA and Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-1949, 2000.
18. Palmqvist R, Stenling R, Oberg A and Landberg G: Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer 34: 1575-1581, 1998.
19. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N and Ooi A: EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118: 1173-1180, 2006.
20. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T and Soria JC: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
21. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ and Medeiros LJ: Activation of mammalian target of rapamycin signalling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169: 2171-2180, 2006.
22. Tang JM, He QY, Guo RX and Chang XJ: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191, 2006.
23. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL and Eng C: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155: 1253-1260, 1999.
24. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJ and Hirsch FR: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170-4176, 2006.
25. Khan AJ, King BL, Smith BD, Smith GL, DiGiovanna MP, Carter D and Haffty BG: Characterization of the HER2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8: 540-548, 2002.
26. Meert AP, Martin B, Verdebout JM, Noel S, Ninane V and Sculier JP: Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC? Lung Cancer 47: 325-336, 2005.
27. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP and Zelefsky MJ: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072-1078, 2006.
28. Glisson BS, Murphy BA, Frenette G, Khuri FR and Forastiere AA: Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20: 1593-1599, 2002.
29. Ford AC and Grandis JR: Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25: 67-73, 2003.
30. Squarize CH, Castilho RM and Santos Pinto D Jr: Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system. J Oral Pathol Med 31: 379-384, 2002.
31. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN and Papadimitrakopoulou VA: Akt activation correlates with adverse outcome in tongue cancer. Cancer 104: 2430-2436, 2005.
32. Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, Castro G Jr and Awada A: Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28: 256-269, 2006.
33. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ and Mao L: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25: 2164-2170, 2007.
34. Oc P, Rhys-Evans PH, Modjtahedi H and Eccles SA: The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol 38: 627-640, 2002.
35. Zamble DB, Mu D, Reardon JT, Sancar A and Lippard SJ: Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35: 10004-10013, 1996.
36. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC and Fouret P: Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13: 3855-3859, 2007.
37. Jun H, Ahn M, Kim H, Park B, Han J, Ahn Y, Jeong H, Son Y, Baek J and Park K: Clinical significance of ERCC1 expression in advanced squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. J Clin Oncol 25(18 Suppl): 6061 (Abstr), 2007.